Roles of Traditional and Next-Generation Probiotics on Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review and Network Meta-Analysis

Non-alcoholic fatty liver disease (NAFLD) and its progressive stage, non-alcoholic steatohepatitis (NASH), are becoming one of the most common chronic liver diseases globally. Lifestyle interventions such as weight reduction, increased physical activity, and maintaining healthy diets play a pivotal...

Full description

Saved in:
Bibliographic Details
Published inAntioxidants Vol. 13; no. 3; p. 329
Main Authors Zhu, Yuezhi, Tan, Jen Kit, Liu, Jia, Goon, Jo Aan
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 07.03.2024
MDPI
Subjects
Online AccessGet full text
ISSN2076-3921
2076-3921
DOI10.3390/antiox13030329

Cover

Abstract Non-alcoholic fatty liver disease (NAFLD) and its progressive stage, non-alcoholic steatohepatitis (NASH), are becoming one of the most common chronic liver diseases globally. Lifestyle interventions such as weight reduction, increased physical activity, and maintaining healthy diets play a pivotal role in managing NAFLD/NASH. Recent studies suggest that the gut microbiome is associated with the pathogenesis of NAFLD/NASH, prompting microbiome-targeted therapy to emerge as a new therapeutic option for NAFLD/NASH. We conducted a systematic review based on the PRISMA statement and employed network meta-analysis to investigate the effects of traditional probiotics and next-generation probiotics (NGPs) on NAFLD/NASH. Comparative analysis reveals that traditional probiotics primarily reduce liver fat deposition and inflammation by improving gut microbiota composition, enhancing intestinal barrier function, and modulating immune responses. In contrast, NGPs demonstrate a more significant therapeutic potential, attributed to their direct effects on inhibiting oxidative stress and their ability to enhance the production of short-chain fatty acids (SCFAs), NGPs appear as a new potential strategy for the management of NAFLD/NASH through their dual action of directly inhibiting oxidative stress and enhancing SCFA production, highlighting the importance of understanding and utilizing the direct and indirect regulatory mechanisms of oxidative stress in the management of NAFLD/NASH.
AbstractList Non-alcoholic fatty liver disease (NAFLD) and its progressive stage, non-alcoholic steatohepatitis (NASH), are becoming one of the most common chronic liver diseases globally. Lifestyle interventions such as weight reduction, increased physical activity, and maintaining healthy diets play a pivotal role in managing NAFLD/NASH. Recent studies suggest that the gut microbiome is associated with the pathogenesis of NAFLD/NASH, prompting microbiome-targeted therapy to emerge as a new therapeutic option for NAFLD/NASH. We conducted a systematic review based on the PRISMA statement and employed network meta-analysis to investigate the effects of traditional probiotics and next-generation probiotics (NGPs) on NAFLD/NASH. Comparative analysis reveals that traditional probiotics primarily reduce liver fat deposition and inflammation by improving gut microbiota composition, enhancing intestinal barrier function, and modulating immune responses. In contrast, NGPs demonstrate a more significant therapeutic potential, attributed to their direct effects on inhibiting oxidative stress and their ability to enhance the production of short-chain fatty acids (SCFAs), NGPs appear as a new potential strategy for the management of NAFLD/NASH through their dual action of directly inhibiting oxidative stress and enhancing SCFA production, highlighting the importance of understanding and utilizing the direct and indirect regulatory mechanisms of oxidative stress in the management of NAFLD/NASH.
Non-alcoholic fatty liver disease (NAFLD) and its progressive stage, non-alcoholic steatohepatitis (NASH), are becoming one of the most common chronic liver diseases globally. Lifestyle interventions such as weight reduction, increased physical activity, and maintaining healthy diets play a pivotal role in managing NAFLD/NASH. Recent studies suggest that the gut microbiome is associated with the pathogenesis of NAFLD/NASH, prompting microbiome-targeted therapy to emerge as a new therapeutic option for NAFLD/NASH. We conducted a systematic review based on the PRISMA statement and employed network meta-analysis to investigate the effects of traditional probiotics and next-generation probiotics (NGPs) on NAFLD/NASH. Comparative analysis reveals that traditional probiotics primarily reduce liver fat deposition and inflammation by improving gut microbiota composition, enhancing intestinal barrier function, and modulating immune responses. In contrast, NGPs demonstrate a more significant therapeutic potential, attributed to their direct effects on inhibiting oxidative stress and their ability to enhance the production of short-chain fatty acids (SCFAs), NGPs appear as a new potential strategy for the management of NAFLD/NASH through their dual action of directly inhibiting oxidative stress and enhancing SCFA production, highlighting the importance of understanding and utilizing the direct and indirect regulatory mechanisms of oxidative stress in the management of NAFLD/NASH.Non-alcoholic fatty liver disease (NAFLD) and its progressive stage, non-alcoholic steatohepatitis (NASH), are becoming one of the most common chronic liver diseases globally. Lifestyle interventions such as weight reduction, increased physical activity, and maintaining healthy diets play a pivotal role in managing NAFLD/NASH. Recent studies suggest that the gut microbiome is associated with the pathogenesis of NAFLD/NASH, prompting microbiome-targeted therapy to emerge as a new therapeutic option for NAFLD/NASH. We conducted a systematic review based on the PRISMA statement and employed network meta-analysis to investigate the effects of traditional probiotics and next-generation probiotics (NGPs) on NAFLD/NASH. Comparative analysis reveals that traditional probiotics primarily reduce liver fat deposition and inflammation by improving gut microbiota composition, enhancing intestinal barrier function, and modulating immune responses. In contrast, NGPs demonstrate a more significant therapeutic potential, attributed to their direct effects on inhibiting oxidative stress and their ability to enhance the production of short-chain fatty acids (SCFAs), NGPs appear as a new potential strategy for the management of NAFLD/NASH through their dual action of directly inhibiting oxidative stress and enhancing SCFA production, highlighting the importance of understanding and utilizing the direct and indirect regulatory mechanisms of oxidative stress in the management of NAFLD/NASH.
Author Tan, Jen Kit
Zhu, Yuezhi
Liu, Jia
Goon, Jo Aan
AuthorAffiliation 2 Department of Nursing, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia
1 Department of Biochemistry, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia
AuthorAffiliation_xml – name: 2 Department of Nursing, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia
– name: 1 Department of Biochemistry, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia
Author_xml – sequence: 1
  givenname: Yuezhi
  surname: Zhu
  fullname: Zhu, Yuezhi
– sequence: 2
  givenname: Jen Kit
  orcidid: 0000-0002-0824-0581
  surname: Tan
  fullname: Tan, Jen Kit
– sequence: 3
  givenname: Jia
  surname: Liu
  fullname: Liu, Jia
– sequence: 4
  givenname: Jo Aan
  orcidid: 0000-0003-1757-3780
  surname: Goon
  fullname: Goon, Jo Aan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38539862$$D View this record in MEDLINE/PubMed
BookMark eNqNkk1PGzEQhlcVVaGUa4-VpV7gsNQfu7HdC4qgAaQ0rQg9W17vLHG6Wae2E8g_68-rQ0JFkCrVPtgav_P4ndG8zfY610GWvSf4lDGJP-kuWvdAGE6bylfZAcW8lzNJyd6z-352FMIUpyUJE1i-yfaZKJkUPXqQ_b5xLQTkGnTrdW0Tr9Mt0l2NRvAQ80vowOt1FH33rrIuWpPUHRq5Lu-3xk1caw0a6BhXaGiX4NGFDaADoONRfzC8ONmwdtTjCDq6CcwTONqwVo6vTj6jPhqvQoRZCht0A0sL91sn8d75n-grRJ33k79VsOFd9rrRbYCj7XmY_Rh8uT2_yoffLq_P-8PclETEnDai5BxDVRdNRQmBgpVUlripTEEaUfU4T62ESjNSAit7Da4oJqbSgGUpWc0Os-sNt3Z6qubezrRfKaetegw4f6e0T4ZbULzBWBihOSdN0WONriQvWCEZkZoIIRPrbMOaL6oZ1Aa66HW7A9196exE3bmlIlj2BOEiEY63BO9-LSBENbPBQNvqDtwiKIYLnL6kXP6HlBQYF0LQJP34Qjp1C58aHRSVghMpabkGfnju_q_tp2FKgmIjMN6F4KFRxsbH4UnF2DZVodZjq3bHNqWdvkh7Iv8j4Q_r6--I
CitedBy_id crossref_primary_10_12944_CRNFSJ_12_2_2
crossref_primary_10_1016_j_nutos_2024_08_009
crossref_primary_10_1186_s10020_024_00945_1
crossref_primary_10_1016_j_fbio_2024_105454
crossref_primary_10_3389_fmed_2024_1490929
crossref_primary_10_3390_biomedicines12112529
crossref_primary_10_1016_j_clnesp_2024_07_1024
crossref_primary_10_1016_j_ecoenv_2025_117969
Cites_doi 10.1186/s12876-019-1047-4
10.1007/s10620-011-1887-4
10.1111/jgh.13742
10.4103/2008-7802.178533
10.3390/ijms24032844
10.1111/1750-3841.15367
10.1039/D0FO01954B
10.1080/13543784.2020.1716333
10.3389/fnut.2022.1037696
10.1016/j.redox.2018.01.009
10.1016/j.tjnut.2023.05.019
10.14715/cmb/2021.67.5.9
10.3390/nu12113225
10.15403/jgld.2014.1121.271.kby
10.1016/S1665-2681(19)31364-X
10.3168/jds.2014-8500
10.3390/ijms23042325
10.1038/s41586-023-06378-w
10.1093/ajcn/nqy358
10.1128/AEM.03004-19
10.3350/cmh.2018.0006
10.3389/fimmu.2022.1047570
10.3390/nu13093211
10.3389/fimmu.2021.678360
10.1016/j.addr.2021.113869
10.1016/bs.pmbts.2022.07.004
10.1111/1751-2980.12561
10.1038/s41598-022-06414-1
10.1016/j.aohep.2022.100769
10.3390/diseases7010027
10.1371/journal.pone.0263931
10.1016/j.clnesp.2020.06.020
10.3390/nu13093192
10.3390/ph16050712
10.1016/j.biopha.2021.111235
10.1080/07315724.2015.1031355
10.3389/fmicb.2023.1123547
10.3390/microorganisms10020297
10.3389/fcimb.2022.997018
10.1016/j.eng.2020.01.017
10.1097/MD.0000000000021464
10.3390/nu12092762
10.1128/Spectrum.00484-21
10.3390/biomedicines9060687
10.1080/17461391.2019.1571114
10.3389/fendo.2022.1087260
10.3390/antiox10122001
10.1053/j.gastro.2020.01.031
10.2147/DMSO.S146339
10.1007/s00018-021-04080-6
10.3390/microorganisms10020452
10.3945/ajcn.113.068890
10.3389/fcimb.2022.863949
10.3390/nu14142945
10.1053/j.gastro.2020.01.051
10.1038/s41598-019-42059-3
10.1080/19490976.2023.2221485
10.3390/biomedicines11020640
10.1530/JOE-20-0018
10.1007/s00394-018-1721-2
10.1016/j.biopha.2023.114300
10.1186/s12876-021-01660-5
10.1016/j.foodres.2019.108590
10.2147/PHMT.S188989
10.1136/bmjgast-2019-000315
10.1093/jn/nxab392
10.1017/S0007114517000204
10.1155/2022/5633403
ContentType Journal Article
Copyright 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2024 by the authors. 2024
Copyright_xml – notice: 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2024 by the authors. 2024
DBID AAYXX
CITATION
NPM
7QR
7T5
7TO
8FD
8FE
8FH
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FR3
GNUQQ
H94
HCIFZ
LK8
M7P
P64
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
7S9
L.6
5PM
DOA
DOI 10.3390/antiox13030329
DatabaseName CrossRef
PubMed
Chemoreception Abstracts
Immunology Abstracts
Oncogenes and Growth Factors Abstracts
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Journals
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
Engineering Research Database
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
Biological Sciences
Biological Science Database
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
PubMed Central (Full Participant titles)
DOAJ Open Access Full Text
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
AIDS and Cancer Research Abstracts
Chemoreception Abstracts
ProQuest Central (New)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
Biological Science Database
ProQuest SciTech Collection
Biotechnology and BioEngineering Abstracts
ProQuest One Academic UKI Edition
Immunology Abstracts
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList AGRICOLA
CrossRef
MEDLINE - Academic
PubMed


Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Engineering
EISSN 2076-3921
ExternalDocumentID oai_doaj_org_article_7f008c8a771f463fab974349319a1889
PMC10968178
38539862
10_3390_antiox13030329
Genre Journal Article
Review
GrantInformation_xml – fundername: HEZE HUIREN CHINESE MEDICINE HOSPITAL
  grantid: FF-2022-261
– fundername: UNIVERSITI KEBANGSAAN MALAYSIA
  grantid: DPK-2022-007
GroupedDBID 53G
5VS
8FE
8FH
AADQD
AAFWJ
AAHBH
AAYXX
ADBBV
AFKRA
AFPKN
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BBNVY
BCNDV
BENPR
BHPHI
CCPQU
CITATION
GROUPED_DOAJ
HCIFZ
HYE
IAO
IHR
ITC
KQ8
LK8
M48
M7P
MODMG
M~E
OK1
PGMZT
PHGZM
PHGZT
PIMPY
PQGLB
PROAC
PUEGO
RPM
NPM
7QR
7T5
7TO
8FD
ABUWG
AZQEC
DWQXO
FR3
GNUQQ
H94
P64
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
7S9
L.6
5PM
ID FETCH-LOGICAL-c518t-2f85770ebd4fb211e4352950fbc41f8b677339eba315e356f0b201cbae09593d3
IEDL.DBID M48
ISSN 2076-3921
IngestDate Wed Aug 27 01:31:46 EDT 2025
Tue Sep 30 17:09:33 EDT 2025
Fri Sep 05 09:57:43 EDT 2025
Thu Sep 04 20:06:15 EDT 2025
Fri Jul 25 11:51:33 EDT 2025
Thu Jan 02 22:37:57 EST 2025
Thu Apr 24 23:09:05 EDT 2025
Wed Oct 01 03:03:25 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords antioxidant
NAFLD/NASH
traditional probiotics
short-chain fatty acids (SCFAs)
next-generation probiotics (NGPs)
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c518t-2f85770ebd4fb211e4352950fbc41f8b677339eba315e356f0b201cbae09593d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0002-0824-0581
0000-0003-1757-3780
OpenAccessLink https://doaj.org/article/7f008c8a771f463fab974349319a1889
PMID 38539862
PQID 2987199259
PQPubID 2032435
ParticipantIDs doaj_primary_oai_doaj_org_article_7f008c8a771f463fab974349319a1889
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10968178
proquest_miscellaneous_3040434279
proquest_miscellaneous_3014004882
proquest_journals_2987199259
pubmed_primary_38539862
crossref_citationtrail_10_3390_antiox13030329
crossref_primary_10_3390_antiox13030329
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20240307
PublicationDateYYYYMMDD 2024-03-07
PublicationDate_xml – month: 3
  year: 2024
  text: 20240307
  day: 7
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Antioxidants
PublicationTitleAlternate Antioxidants (Basel)
PublicationYear 2024
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Yao (ref_15) 2021; 7
Michel (ref_69) 2020; 29
ref_12
Esposito (ref_13) 2022; 79
Malaguarnera (ref_42) 2012; 57
ref_56
ref_11
Khan (ref_16) 2023; 620
Mofidi (ref_29) 2017; 117
ref_55
ref_10
ref_53
ref_52
Sun (ref_14) 2019; 126
ref_19
ref_18
ref_17
Eslamparast (ref_26) 2014; 99
Shavakhi (ref_24) 2013; 4
Amiri (ref_67) 2022; 9
Scorletti (ref_33) 2020; 158
Abhari (ref_31) 2020; 39
Escouto (ref_45) 2023; 153
Farzanegi (ref_20) 2019; 19
Kim (ref_59) 2020; 86
ref_61
ref_60
Raftar (ref_54) 2022; 12
Zhu (ref_49) 2022; 68
Li (ref_57) 2022; 13
ref_21
ref_65
ref_64
ref_63
Borrelli (ref_22) 2018; 15
Purohit (ref_7) 2022; 191
Cirillo (ref_3) 2019; 10
Sepideh (ref_27) 2016; 35
Crommen (ref_47) 2022; 152
Yang (ref_51) 2020; 11
ref_70
Ahn (ref_37) 2019; 9
Sarwar (ref_4) 2018; 11
ref_34
Rong (ref_62) 2022; 13
Han (ref_58) 2023; 15
ref_38
Kobyliak (ref_36) 2018; 27
Deng (ref_68) 2020; 245
Beisner (ref_66) 2021; 12
Asgharian (ref_28) 2016; 7
Wong (ref_39) 2013; 12
Nabavi (ref_25) 2014; 97
Bomhof (ref_32) 2019; 58
Padda (ref_2) 2021; 13
Manzhalii (ref_35) 2017; 18
Aller (ref_43) 2011; 15
ref_1
Chen (ref_40) 2019; 109
Kumar (ref_23) 2021; 176
Behrouz (ref_30) 2020; 85
Duseja (ref_44) 2019; 6
Barcelos (ref_46) 2023; 28
ref_9
ref_8
Zhou (ref_50) 2017; 32
ref_5
Sayari (ref_48) 2018; 24
ref_6
Cai (ref_41) 2020; 99
(ref_71) 2020; 158
References_xml – volume: 13
  start-page: e17321
  year: 2021
  ident: ref_2
  article-title: Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus
  publication-title: Cureus
– ident: ref_9
  doi: 10.1186/s12876-019-1047-4
– volume: 57
  start-page: 545
  year: 2012
  ident: ref_42
  article-title: Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis
  publication-title: Dig. Dis. Sci.
  doi: 10.1007/s10620-011-1887-4
– volume: 32
  start-page: 1640
  year: 2017
  ident: ref_50
  article-title: Clostridium butyricum B1 alleviates high-fat diet-induced steatohepatitis in mice via enterohepatic immunoregulation
  publication-title: J. Gastroenterol. Hepatol.
  doi: 10.1111/jgh.13742
– volume: 7
  start-page: 59
  year: 2016
  ident: ref_28
  article-title: The Effect of Symbiotic Supplementation on Liver Enzymes, C-reactive Protein and Ultrasound Findings in Patients with Non-alcoholic Fatty Liver Disease: A Clinical Trial
  publication-title: Int. J. Prev. Med.
  doi: 10.4103/2008-7802.178533
– ident: ref_1
  doi: 10.3390/ijms24032844
– volume: 85
  start-page: 3611
  year: 2020
  ident: ref_30
  article-title: Effects of probiotic and prebiotic supplementation on metabolic parameters, liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease: A randomized clinical trial
  publication-title: J. Food Sci.
  doi: 10.1111/1750-3841.15367
– volume: 11
  start-page: 10675
  year: 2020
  ident: ref_51
  article-title: Amelioration of non-alcoholic fatty liver disease by sodium butyrate is linked to the modulation of intestinal tight junctions in db/db mice
  publication-title: Food Funct.
  doi: 10.1039/D0FO01954B
– volume: 29
  start-page: 93
  year: 2020
  ident: ref_69
  article-title: Effectiveness of lifestyle interventions in NAFLD (nonalcoholic fatty liver disease)—How are clinical trials affected
  publication-title: Expert Opin. Investig. Drugs.
  doi: 10.1080/13543784.2020.1716333
– volume: 9
  start-page: 1037696
  year: 2022
  ident: ref_67
  article-title: Mechanistic insights into the pleiotropic effects of butyrate as a potential therapeutic agent on NAFLD management: A systematic review
  publication-title: Front. Nutr.
  doi: 10.3389/fnut.2022.1037696
– volume: 15
  start-page: 467
  year: 2018
  ident: ref_22
  article-title: Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches
  publication-title: Redox Biol.
  doi: 10.1016/j.redox.2018.01.009
– volume: 15
  start-page: 1090
  year: 2011
  ident: ref_43
  article-title: Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: A double blind randomized clinical trial
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 153
  start-page: 1984
  year: 2023
  ident: ref_45
  article-title: Probiotic Supplementation, Hepatic Fibrosis, and the Microbiota Profile in Patients with Nonalcoholic Steatohepatitis: A Randomized Controlled Trial
  publication-title: J. Nutr.
  doi: 10.1016/j.tjnut.2023.05.019
– volume: 68
  start-page: 64
  year: 2022
  ident: ref_49
  article-title: Effects of Clostridium butyricum Capsules Combined with Rosuvastatin on Intestinal Flora, Lipid Metabolism, Liver Function and Inflammation in NAFLD Patients
  publication-title: Cell Mol. Biol.
  doi: 10.14715/cmb/2021.67.5.9
– ident: ref_61
  doi: 10.3390/nu12113225
– volume: 27
  start-page: 41
  year: 2018
  ident: ref_36
  article-title: A Multi-strain Probiotic Reduces the Fatty Liver Index, Cytokines and Aminotransferase levels in NAFLD Patients: Evidence from a Randomized Clinical Trial
  publication-title: J. Gastrointestin. Liver Dis.
  doi: 10.15403/jgld.2014.1121.271.kby
– volume: 12
  start-page: 256
  year: 2013
  ident: ref_39
  article-title: Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study
  publication-title: Ann. Hepatol.
  doi: 10.1016/S1665-2681(19)31364-X
– volume: 97
  start-page: 7386
  year: 2014
  ident: ref_25
  article-title: Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease
  publication-title: J. Dairy Sci.
  doi: 10.3168/jds.2014-8500
– ident: ref_60
  doi: 10.3390/ijms23042325
– volume: 620
  start-page: 381
  year: 2023
  ident: ref_16
  article-title: Synergy and oxygen adaptation for development of next-generation probiotics
  publication-title: Nature
  doi: 10.1038/s41586-023-06378-w
– volume: 109
  start-page: 1611
  year: 2019
  ident: ref_40
  article-title: Yogurt improves insulin resistance and liver fat in obese women with nonalcoholic fatty liver disease and metabolic syndrome: A randomized controlled trial
  publication-title: Am. J. Clin. Nutr.
  doi: 10.1093/ajcn/nqy358
– volume: 86
  start-page: e03004
  year: 2020
  ident: ref_59
  article-title: Akkermansia muciniphila Prevents Fatty Liver Disease, Decreases Serum Triglycerides, and Maintains Gut Homeostasis
  publication-title: Appl. Environ. Microbiol.
  doi: 10.1128/AEM.03004-19
– volume: 24
  start-page: 331
  year: 2018
  ident: ref_48
  article-title: Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease
  publication-title: Clin. Mol. Hepatol.
  doi: 10.3350/cmh.2018.0006
– volume: 13
  start-page: 1047570
  year: 2022
  ident: ref_57
  article-title: Akkermansia muciniphila suppressing nonalcoholic steatohepatitis associated tumorigenesis through CXCR6(+) natural killer T cells
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2022.1047570
– ident: ref_10
  doi: 10.3390/nu13093211
– volume: 12
  start-page: 678360
  year: 2021
  ident: ref_66
  article-title: Prebiotic Inulin and Sodium Butyrate Attenuate Obesity-Induced Intestinal Barrier Dysfunction by Induction of Antimicrobial Peptides
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.678360
– volume: 176
  start-page: 113869
  year: 2021
  ident: ref_23
  article-title: Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis
  publication-title: Adv. Drug Deliv. Rev.
  doi: 10.1016/j.addr.2021.113869
– volume: 191
  start-page: 187
  year: 2022
  ident: ref_7
  article-title: Gut microbiome and non-alcoholic fatty liver disease
  publication-title: Prog. Mol. Biol. Transl. Sci.
  doi: 10.1016/bs.pmbts.2022.07.004
– volume: 18
  start-page: 698
  year: 2017
  ident: ref_35
  article-title: Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis: A pilot trial
  publication-title: J. Dig. Dis.
  doi: 10.1111/1751-2980.12561
– volume: 12
  start-page: 2453
  year: 2022
  ident: ref_54
  article-title: The anti-inflammatory effects of Akkermansia muciniphila and its derivates in HFD/CCL4-induced murine model of liver injury
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-022-06414-1
– volume: 28
  start-page: 100769
  year: 2023
  ident: ref_46
  article-title: Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: A double-blind placebo-controlled randomized study
  publication-title: Ann. Hepatol.
  doi: 10.1016/j.aohep.2022.100769
– ident: ref_63
  doi: 10.3390/diseases7010027
– ident: ref_70
  doi: 10.1371/journal.pone.0263931
– volume: 39
  start-page: 53
  year: 2020
  ident: ref_31
  article-title: The effects of Bacillus coagulans supplementation in patients with non-alcoholic fatty liver disease: A randomized, placebo-controlled, clinical trial
  publication-title: Clin. Nutr. ESPEN
  doi: 10.1016/j.clnesp.2020.06.020
– ident: ref_38
  doi: 10.3390/nu13093192
– ident: ref_8
  doi: 10.3390/ph16050712
– ident: ref_64
  doi: 10.1016/j.biopha.2021.111235
– volume: 35
  start-page: 500
  year: 2016
  ident: ref_27
  article-title: Effects of Multistrain Probiotic Supplementation on Glycemic and Inflammatory Indices in Patients with Nonalcoholic Fatty Liver Disease: A Double-Blind Randomized Clinical Trial
  publication-title: J. Am. Coll. Nutr.
  doi: 10.1080/07315724.2015.1031355
– ident: ref_56
  doi: 10.3389/fmicb.2023.1123547
– ident: ref_17
  doi: 10.3390/microorganisms10020297
– ident: ref_6
  doi: 10.3389/fcimb.2022.997018
– volume: 7
  start-page: 679
  year: 2021
  ident: ref_15
  article-title: An Update on the Efficacy and Functionality of Probiotics for the Treatment of Non-Alcoholic Fatty Liver Disease
  publication-title: Engineering
  doi: 10.1016/j.eng.2020.01.017
– volume: 99
  start-page: e21464
  year: 2020
  ident: ref_41
  article-title: Protective effect of probiotics in patients with non-alcoholic fatty liver disease
  publication-title: Medicine
  doi: 10.1097/MD.0000000000021464
– ident: ref_21
  doi: 10.3390/nu12092762
– ident: ref_52
  doi: 10.1128/Spectrum.00484-21
– ident: ref_19
  doi: 10.3390/biomedicines9060687
– volume: 19
  start-page: 994
  year: 2019
  ident: ref_20
  article-title: Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): Roles of oxidative stress and inflammation
  publication-title: Eur. J. Sport Sci.
  doi: 10.1080/17461391.2019.1571114
– volume: 13
  start-page: 1087260
  year: 2022
  ident: ref_62
  article-title: Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
  publication-title: Front. Endocrinol.
  doi: 10.3389/fendo.2022.1087260
– ident: ref_53
  doi: 10.3390/antiox10122001
– volume: 158
  start-page: 1597
  year: 2020
  ident: ref_33
  article-title: Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2020.01.031
– volume: 11
  start-page: 533
  year: 2018
  ident: ref_4
  article-title: Obesity and nonalcoholic fatty liver disease: Current perspectives
  publication-title: Diabetes Metab. Syndr. Obes.
  doi: 10.2147/DMSO.S146339
– volume: 79
  start-page: 76
  year: 2022
  ident: ref_13
  article-title: Outlook on next-generation probiotics from the human gut
  publication-title: Cell. Mol. Life Sci.
  doi: 10.1007/s00018-021-04080-6
– ident: ref_18
  doi: 10.3390/microorganisms10020452
– volume: 99
  start-page: 535
  year: 2014
  ident: ref_26
  article-title: Synbiotic supplementation in nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled pilot study
  publication-title: Am. J. Clin. Nutr.
  doi: 10.3945/ajcn.113.068890
– ident: ref_11
  doi: 10.3389/fcimb.2022.863949
– ident: ref_55
  doi: 10.3390/nu14142945
– volume: 158
  start-page: 1984
  year: 2020
  ident: ref_71
  article-title: Therapeutic Landscape for NAFLD in 2020
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2020.01.051
– volume: 9
  start-page: 5688
  year: 2019
  ident: ref_37
  article-title: Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-019-42059-3
– volume: 15
  start-page: 2221485
  year: 2023
  ident: ref_58
  article-title: Akkermansia muciniphila inhibits nonalcoholic steatohepatitis by orchestrating TLR2-activated γδT17 cell and macrophage polarization
  publication-title: Gut Microbes
  doi: 10.1080/19490976.2023.2221485
– ident: ref_5
  doi: 10.3390/biomedicines11020640
– volume: 245
  start-page: 425
  year: 2020
  ident: ref_68
  article-title: SCFAs alleviated steatosis and inflammation in mice with NASH induced by MCD
  publication-title: J. Endocrinol.
  doi: 10.1530/JOE-20-0018
– volume: 58
  start-page: 1735
  year: 2019
  ident: ref_32
  article-title: Histological improvement of non-alcoholic steatohepatitis with a prebiotic: A pilot clinical trial
  publication-title: Eur. J. Nutr.
  doi: 10.1007/s00394-018-1721-2
– ident: ref_65
  doi: 10.1016/j.biopha.2023.114300
– ident: ref_34
  doi: 10.1186/s12876-021-01660-5
– volume: 126
  start-page: 108590
  year: 2019
  ident: ref_14
  article-title: A potential species of next-generation probiotics? The dark and light sides of Bacteroides fragilis in health
  publication-title: Food. Res. Int.
  doi: 10.1016/j.foodres.2019.108590
– volume: 10
  start-page: 89
  year: 2019
  ident: ref_3
  article-title: Pediatric non-alcoholic fatty liver disease: Current perspectives on diagnosis and management
  publication-title: Pediatr. Health Med. Ther.
  doi: 10.2147/PHMT.S188989
– volume: 4
  start-page: 531
  year: 2013
  ident: ref_24
  article-title: Effect of a Probiotic and Metformin on Liver Aminotransferases in Non-alcoholic Steatohepatitis: A Double Blind Randomized Clinical Trial
  publication-title: Int. J. Prev. Med.
– volume: 6
  start-page: e000315
  year: 2019
  ident: ref_44
  article-title: High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): A randomised, double-blind, proof of concept study
  publication-title: BMJ Open. Gastroenterol.
  doi: 10.1136/bmjgast-2019-000315
– volume: 152
  start-page: 408
  year: 2022
  ident: ref_47
  article-title: A Specifically Tailored Multistrain Probiotic and Micronutrient Mixture Affects Nonalcoholic Fatty Liver Disease-Related Markers in Patients with Obesity after Mini Gastric Bypass Surgery
  publication-title: J. Nutr.
  doi: 10.1093/jn/nxab392
– volume: 117
  start-page: 662
  year: 2017
  ident: ref_29
  article-title: Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: A pilot, randomised, double-blind, placebo-controlled, clinical trial
  publication-title: Br. J. Nutr.
  doi: 10.1017/S0007114517000204
– ident: ref_12
  doi: 10.1155/2022/5633403
SSID ssj0000913809
Score 2.3346436
SecondaryResourceType review_article
Snippet Non-alcoholic fatty liver disease (NAFLD) and its progressive stage, non-alcoholic steatohepatitis (NASH), are becoming one of the most common chronic liver...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 329
SubjectTerms antioxidant
Clinical outcomes
Comparative analysis
Digestive system
Fatty acids
Fatty liver
Gastrointestinal tract
Hepatitis
Immune response
Inflammation
Intervention
Intestinal microflora
intestinal microorganisms
intestines
lifestyle
Lifestyles
Lipids
liver
Liver diseases
Medical Subject Headings-MeSH
Meta-analysis
Metabolism
Microbiomes
Microbiota
NAFLD/NASH
next-generation probiotics (NGPs)
Oxidative stress
pathogenesis
Patients
Physical activity
Prebiotics
Probiotics
Review
short-chain fatty acids (SCFAs)
Systematic review
therapeutics
traditional probiotics
weight loss
SummonAdditionalLinks – databaseName: DOAJ Open Access Full Text
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1di9QwFA2yT_ogrp_jrhJB0H0o2zRNk_g2ug6D7A7iurBvJUkTdkBacbqg_8yf571Jp07FjxdfCm0vJc29yT2nuT0h5LljVSgaKTJnuM9K0bjMClPAoQoQI8ih8W_ks1W1vCjfXYrLna2-sCYsyQOnjjuWAbKUU0ZKFsqKB2MBAfNSQ-gYplT8dQ_S2A6ZinOwZlzlOqk0cuD1xwaLB7_ijJ3ziCd_ZqEo1v87hPlroeRO5lncIbcHyEjnqan75IZv75JbO0KC98j3D6jLRLtAIfc06_R9j5q2oStktklbGq_S91F3CbWZKZytujabp01y144uTN9_o6dYqUFP0sINfbmaL05PjtKzJtZYCdx3Vx5Lsvv1Bi3Pl0ev6Jyej-rQNC09DC2JBef0zPcm22qh3CcXi7cf3yyzYU-GzAmm-qwISkiZe9uUwQJ59AC3Ci3yYF3JgrKVlNDd3hrOhOfocAsQw1njowRywx-QvbZr_SNCnXCaBy55pULJGmWKMojCS64r6fMqzEi29VHtBsFy3DfjUw3EBX1aT306Iy9G-89JquOPlq_R5aMVSmzHCxB49RB49b8Cb0YOtwFTD-N-UxcaCKjWwCln5Nl4G0YsLsOY1nfXmzqSWpw4i7_ZoOpRWUh4zsMUg2NrOSAsDUR0RtQkOievM73Trq-icjgDwqqYVI__RwcckJsFILxYkCcPyV7_5do_AYTW26dxMP4AJJA5-w
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fa9UwFA7z7kUfxN9enRJB0D2U3SZNkwoid26Xi2xlbA72VtI0cReknbsd6H_mn-c5SdutonsptDmEtOfk5HzJ6XcIeWvi1LFKishobqNEVCYqhWZwSR3YCGJo_Bv5ME-Xp8mXM3G2QfL-XxhMq-x9onfUVWNwj3yHATjGVEmRfbr4EWHVKDxd7Uto6K60QvXRU4zdIZsMqypPyObufn50POy6IAummmWBvZED3t_RmFT4Ez35jPs483p18iT-_4o8_06gvLEiLR6Q-10oSedB9w_Jhq0fkXs3CAYfk9_HyNdEG0dhTapWYd-P6rqiOSLewDmNT-mR52NCzmYKd3lTR_NQPHdl6EK37S96gBkcdC8c6ND3-XxxsLcd-hpJY4Zw25xbTNVuV2uUPFluf6BzejKwRtNwJNGNxCei00Pb6qjnSHlCThf7Xz8vo65WQ2Tge7cRc0pIObNllbgSQKWFMIxlYuZKk8ROlamU8LltqXksLEdDKCH0MKW2nhq54k_JpG5q-5xQI0zGHZc8VS6JK6VZ4gSzkmeptLPUTUnU66gwHZE51tP4XgCgQZ0WY51OybtB_iJQePxXchdVPkgh9bZ_0Fx-K7qZXEgHYZNRWsrYJSl3ugRIxpMMfJmOlYJOtnqDKTp_sC6urXdK3gzNMJPxeEbXtrlaFx7sokNlt8kgG1LCJPTzLNjgMFoOkVcGAHVK1Mg6R68zbqlX555RPAYgq2KpXtw-9pfkLoOYzqfgyS0yaS-v7CuIydrydTfR_gA1nDlx
  priority: 102
  providerName: ProQuest
Title Roles of Traditional and Next-Generation Probiotics on Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review and Network Meta-Analysis
URI https://www.ncbi.nlm.nih.gov/pubmed/38539862
https://www.proquest.com/docview/2987199259
https://www.proquest.com/docview/3014004882
https://www.proquest.com/docview/3040434279
https://pubmed.ncbi.nlm.nih.gov/PMC10968178
https://doaj.org/article/7f008c8a771f463fab974349319a1889
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 2076-3921
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000913809
  issn: 2076-3921
  databaseCode: KQ8
  dateStart: 20120101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2076-3921
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000913809
  issn: 2076-3921
  databaseCode: DOA
  dateStart: 20120101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2076-3921
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000913809
  issn: 2076-3921
  databaseCode: M~E
  dateStart: 20120101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 2076-3921
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000913809
  issn: 2076-3921
  databaseCode: RPM
  dateStart: 20120101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 2076-3921
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000913809
  issn: 2076-3921
  databaseCode: BENPR
  dateStart: 20120301
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVFZP
  databaseName: Scholars Portal Journals: Open Access
  customDbUrl:
  eissn: 2076-3921
  dateEnd: 20250731
  omitProxy: true
  ssIdentifier: ssj0000913809
  issn: 2076-3921
  databaseCode: M48
  dateStart: 20120901
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3va9QwGA66fdEP4m9vziOCoPtQvSRtkwoiN7fjkF0Zmwf7VtI0cQejdXcdbP-Zf57vm_bqKqf4pdD2JbTJm-R5mqdPCHljWOx4IaPAaGGDMCpMkEeawyF2kCPIofFv5FkaT-fh17Po7Lf-qa3A1UZqh_tJzZcX768vbz5Dh_-EjBMo-weNusBrHIxHgid3yTbMShwzfNZCfT8qJ0wor_jgQN0DgAWs8XDcUERvjvJW_pvw558yylvz0uQhedACSjpuMuARuWPLx-T-LZvBJ-TnCbo20cpRmJmKRfP1j-qyoCny3sZ5Gq_SY-_KhM7NFM7SqgzGzRa6C0Mnuq5v6BHqOOhBs6xD36XjydHBXlNWLxp1wnV1blGwXS9WGHk63ftIx_S0846mzcJE-yRejk5nttbB2inlKZlPDr99mQbtjg2BiZiqA-5UJOXI5kXocqCWFsAYT6KRy03InMpjKaG6ba4Fi6zAdMgBgJhcW2-QXIhnZKusSvuCUBOZRDghRaxcyAqleegibqVIYmlHsRuQYN1GmWntzHFXjYsMaA22adZv0wF528X_aIw8_hq5j03eRaEBt79QLb9nbX_OpAPwZJSWkrkwFk7nQMxEmMCIpplSUMjuOmGydVJnPAF6miTAOAfkdXcb-jMu0ujSVlerzFNeHFb5v2LQEynkEsp53uRg97QC8FcCNHVAVC87e6_Tv1Muzr2vOAM6q5hUO_9dVS_JPQ4gz2vy5C7ZqpdX9hWAtDofku39w_T4ZOg_cgx9X_wFHh0-Og
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKewAOiDcLBYwEgh6iJnYSJ0gV2rJdbeluVPUh9ZY6jk1XQknppoL-M078NmacRxsEvfUSKclk5GjG87DH3xDyVnmhYbkIHCW5dvwgV04WSAaX0ICOYA6Np5FnSTg59L8cBUdL5Hd7FgbLKlubaA11XipcI19nkBxjqWQQfzr97mDXKNxdbVtoyKa1Qr5hIcaagx07-uIHpHCLje0RyPsdY-Otg88Tp-ky4CigrBxmokAIV2e5bzJIhzQEECwOXJMp3zNRFgrBeawzyb1Ac_yFDJymyqS2oL45B763yAp8xWFWrWxuJbt73SoPom5GblyjRQIbd11iEeNP9Bwut3HtpTe0TQP-Fen-XbB5xQOO75N7TehKh7WuPSBLunhI7l4BNHxEfu0hPhQtDQUfmM_rdUYqi5wmmGHXGNf4lO5a_CfEiKZwl5SFM6yb9c4VHcuquqBTrBiho3oDiX5IhuPpaK3m1aPGiuSqPNFYGl7NF0i5P1n7SId0v0OppvUWSDMSW_hOZ7qSTovJ8pgc3ojUnpDloiz0M0JVoGJuuOBhZHwvjyTzTcC04HEotBuaAXFaGaWqAU7H_h3fUkigUKZpX6YD8r6jP60hQ_5LuYki76gQ6ts-KM--po3lSIWBME1FUgjP-CE3MoMUkPsx2E7pRREwWW0VJm3szyK9nC0D8qZ7DZYDt4NkocvzRWqTazTg7DoaRF_ymQA-T2sd7EbLIdKLISEekKinnb3f6b8p5icWwdyDxDnyRPT8-rG_JrcnB7NpOt1Odl6QOwziSVv-J1bJcnV2rl9CPFhlr5pJR8nxTc_zP4JXda4
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELdGJyF4QPynMMBIINhD1MROYgdpQh1d1bEuqjYm7S04jr1VmpKxZoJ9Mz4Dn4q7_NuKYG97qdTkZDm689397PPvCHmrvdCyTASOVtw4fpBpJw0Ug5_Qgo0ghsbbyLtxODnwvxwGhyvkd3sXBssqW59YOeqs0LhHPmAAjrFUMogGtimLmI3Gn06_O9hBCk9a23YaqmmzkG1UdGPNJY8dc_ED4NxiY3sEun_H2Hjr6-eJ03QccDRIlg6zMhDCNWnm2xSgkYFkgkWBa1Pte1amoRCcRyZV3AsMx89JIYDqVJmK4DfjMO4tsirwvmiPrG5uxbO9bscHGTilG9XMkTCMO1BY0PgTo4jLqxz3MjJWDQT-lfX-Xbx5JRqO75N7TRpLh7XdPSArJn9I7l4hN3xEfu0hVxQtLIV4mM3rPUeq8ozGiLZrvmt8SmcVFxTyRVP4Fxe5M6wb9841HauyvKBTrB6ho_owiX6Ih-PpaL0ea0kaq5PL4thgmXg5X6Dk_mT9Ix3S_Y6xmtbHIc1MqiJ4umtK5bT8LI_JwY1o7Qnp5UVunhGqAx1xywUPpfW9TCrm24AZUGgojBvaPnFaHSW6IVHHXh4nCYAp1GmyrNM-ed_Jn9b0If-V3ESVd1JI-109KM6OksaLJMJCyqalEsKzfsitSgEOcj8CP6o8KWGQtdZgksYXLZLLldMnb7rX4EXwaEjlpjhfJBXQRmfOrpNBJiafCRjnaW2D3Ww5ZH0RgOM-kUvWufQ5y2_y-XHFZu4BiJaekM-vn_trchvWezLdjndekDsMUsuqElCskV55dm5eQmpYpq-aNUfJt5te5n8A8a556A
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Roles+of+Traditional+and+Next-Generation+Probiotics+on+Non-Alcoholic+Fatty+Liver+Disease+%28NAFLD%29+and+Non-Alcoholic+Steatohepatitis+%28NASH%29%3A+A+Systematic+Review+and+Network+Meta-Analysis&rft.jtitle=Antioxidants&rft.au=Zhu%2C+Yuezhi&rft.au=Tan%2C+Jen+Kit&rft.au=Liu%2C+Jia&rft.au=Goon%2C+Jo+Aan&rft.date=2024-03-07&rft.issn=2076-3921&rft.eissn=2076-3921&rft.volume=13&rft.issue=3&rft.spage=329&rft_id=info:doi/10.3390%2Fantiox13030329&rft.externalDBID=n%2Fa&rft.externalDocID=10_3390_antiox13030329
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2076-3921&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2076-3921&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2076-3921&client=summon